UK markets closed
  • FTSE 100

    7,608.08
    +6.23 (+0.08%)
     
  • FTSE 250

    18,279.42
    +180.74 (+1.00%)
     
  • AIM

    726.18
    +1.20 (+0.17%)
     
  • GBP/EUR

    1.1533
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.2201
    -0.0005 (-0.04%)
     
  • Bitcoin GBP

    22,108.29
    -51.37 (-0.23%)
     
  • CMC Crypto 200

    579.66
    +0.90 (+0.15%)
     
  • S&P 500

    4,288.05
    -11.65 (-0.27%)
     
  • DOW

    33,507.50
    -158.84 (-0.47%)
     
  • CRUDE OIL

    90.77
    -0.94 (-1.02%)
     
  • GOLD FUTURES

    1,864.60
    -14.00 (-0.75%)
     
  • NIKKEI 225

    31,857.62
    -14.90 (-0.05%)
     
  • HANG SENG

    17,809.66
    +436.63 (+2.51%)
     
  • DAX

    15,386.58
    +63.08 (+0.41%)
     
  • CAC 40

    7,135.06
    +18.82 (+0.26%)
     

Medigene to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Medigene AG
Medigene AG

MARTINSRIED, Germany and MUNICH, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023.

Members of Medigene's management team will participate in a fireside chat and will be available for virtual one-on-one meetings with registered investors.

About Medigene
Medigene AG (FSE: MDG1) is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product enhancement and product development technologies, allows Medigene to create best-in-class differentiated, T Cell Receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene

Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

LifeSci Advisors

Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.